Prometheus Biosciences (RXDX) Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last twelve months. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXDX, but not buy additional shares or sell existing shares.
View RXDX analyst ratings or view top-rated stocks.

10 brokers have issued 1 year target prices for Prometheus Biosciences' shares. Their RXDX share price forecasts range from $111.00 to $200.00. On average, they predict the company's stock price to reach $162.70 in the next twelve months. This suggests that the stock has a possible downside of 18.6%.
View analysts price targets for RXDX or view top-rated stocks among Wall Street analysts.

Prometheus Biosciences, Inc. (NASDAQ:RXDX) posted its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.06. The biopharmaceutical company had revenue of $1.11 million for the quarter, compared to analyst estimates of $0.46 million. Prometheus Biosciences had a negative net margin of 3,768.76% and a negative trailing twelve-month return on equity of 33.50%. The company's quarterly revenue was down 71.8% on a year-over-year basis.

Vanguard Russell 2000 Growth ETF holds 27,868 shares of RXDX stock, representing 0.58% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD).

(RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX."

Prometheus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Walleye Trading LLC (0.00%), Citadel Advisors LLC (0.00%), HAP Trading LLC (0.00%), Citigroup Inc. (0.00%), Belvedere Trading LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Joseph C Papa, Keith W Marshall, Mark C Mckenna, Mark Stenhouse, Perceptive Advisors Llc and Sinai Intellectual Prop Cedars.
View institutional ownership trends.

One share of RXDX stock can currently be purchased for approximately $199.92.

Prometheus Biosciences (NASDAQ:RXDX) has a market capitalization of $9.56 billion and generates $6.81 million in revenue each year. The biopharmaceutical company earns $-141,750,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.

Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The official website for the company is ignyta.com. The biopharmaceutical company can be reached via phone at 858-422-4300 or via email at nkurdi@prometheusbiosciences.com.